Lumefantrine

Lumefantrine
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa609024
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • US: C
Identifiers
IUPAC name
  • 2-(Dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.133.797 Edit this at Wikidata
Chemical and physical data
FormulaC30H32Cl3NO
Molar mass528.94 g·mol−1
3D model (JSmol)
Melting point130 to 132 °C (266 to 270 °F)
SMILES
  • Clc1ccc(cc1)\C=C3\c4c(c2c(cc(Cl)cc23)C(O)CN(CCCC)CCCC)ccc(Cl)c4
InChI
  • InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15- checkY
  • Key:DYLGFOYVTXJFJP-MYYYXRDXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Lumefantrine (or benflumetol) is an antimalarial drug. It is only used in combination with artemether. The term "co-artemether" is sometimes used to describe this combination.[1] Lumefantrine has a much longer half-life compared to artemether, and is therefore thought to clear any residual parasites that remain after combination treatment.[2]

Lumefantrine, along with pyronaridine and naphtoquine, were synthesized during the Chinese Project 523 antimalaria drug research effort initiated in 1967; these compounds are all used in combination antimalaria therapies.[3][4][5]

See also

References

  1. ↑ Toovey S, Jamieson A, Nettleton G (2003). "Successful co-artemether (artemether-lumefantrine) clearance of falciparum malaria in a patient with severe cholera in Mozambique". Travel Medicine and Infectious Disease. 1 (3): 177–9. doi:10.1016/j.tmaid.2003.09.002. PMID 17291911.
  2. ↑ White, Nicholas J.; van Vugt, Michele; Ezzet, Farkad (1999). "Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine". Clinical Pharmacokinetics. 37 (2): 105–125. doi:10.2165/00003088-199937020-00002. ISSN 0312-5963. PMID 10496300. S2CID 72714420.
  3. ↑ Cui, Liwang; Su, Xin-zhuan (2009). "Discovery, mechanisms of action and combination therapy of artemisinin". Expert Review of Anti-infective Therapy. 7 (8): 999–1013. doi:10.1586/eri.09.68. PMC 2778258. PMID 19803708.
  4. ↑ Benjamin, John; Moore, Brioni; Lee, Sook Ting; Senn, Michèle; Griffin, Susan; Lautu, Dulci; Salman, Sam; Siba, Peter; Mueller, Ivo; Davis, Timothy M. E. (2012). "Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: A Tolerability, Safety, and Preliminary Efficacy Study". Antimicrobial Agents and Chemotherapy. 56 (5): 2465–2471. doi:10.1128/AAC.06248-11. PMC 3346652. PMID 22330921.
  5. ↑ Laman, M; Moore, BR; Benjamin, JM; Yadi, G; Bona, C; Warrel, J; Kattenberg, JH; Koleala, T; Manning, L; Kasian, B; Robinson, LJ; Sambale, N; Lorry, L; Karl, S; Davis, WA; Rosanas-Urgell, A; Mueller, I; Siba, PM; Betuela, I; Davis, TM (2014). "Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial". PLOS Med. 11 (12): e1001773. doi:10.1371/journal.pmed.1001773. PMC 4280121. PMID 25549086.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.